GLP-1 Metabolic Baseline CMP, CBC, fasting glucose & insulin (HOMA-IR), A1C, full lipid panel, TSH & free T4, hs-CRP, ferritin, vitamin D, B12, folate
Patients with known allergy or sensitivity to local anesthetics of the amide type should inform their provider before starting
Whether the lean mass preservation observed with combination liraglutide-plus-exercise translates to higher-magnitude weight loss on more potent agents is a question the published RCT literature has not yet definitively answered
Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists
Cherney DZI, Bjornstad P, Perkins BA et al (2021) Kidney effects of empagliflozin in people with type 1 diabetes
Try this routine: Drink a glass of water after waking